163 related articles for article (PubMed ID: 29656114)
1. Synergistic action of dual IGF1/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation of STAT6 and PDAP1.
Weston VJ; Wei W; Stankovic T; Kearns P
Exp Hematol; 2018 Jul; 63():52-63.e5. PubMed ID: 29656114
[TBL] [Abstract][Full Text] [Related]
2. Upstream and downstream mechanisms for the promoting effects of IGF-1 on differentiation of spermatogonia to primary spermatocytes.
Shen G; Wu R; Liu B; Dong W; Tu Z; Yang J; Xu Z; Pan T
Life Sci; 2014 Apr; 101(1-2):49-55. PubMed ID: 24582811
[TBL] [Abstract][Full Text] [Related]
3. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
Flanigan SA; Pitts TM; Newton TP; Kulikowski GN; Tan AC; McManus MC; Spreafico A; Kachaeva MI; Selby HM; Tentler JJ; Eckhardt SG; Leong S
Clin Cancer Res; 2013 Nov; 19(22):6219-29. PubMed ID: 24045180
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity induced by manipulation of signal transduction pathways is associated with down-regulation of Bcl-2 but not Mcl-1 in MCF-7 human breast cancer.
Hu Y; Dragowska WH; Wallis A; Duronio V; Mayer L
Breast Cancer Res Treat; 2001 Nov; 70(1):11-20. PubMed ID: 11767000
[TBL] [Abstract][Full Text] [Related]
5. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
6. Specific inhibition of basal mitogen-activated protein kinases and phosphatidylinositol 3 kinase activities in leukemia cells: a possible therapeutic role for the kinase inhibitors.
Champelovier P; El Atifi M; Pautre V; Rostaing B; Berger F; Seigneurin D
Exp Hematol; 2008 Jan; 36(1):28-36. PubMed ID: 17949889
[TBL] [Abstract][Full Text] [Related]
7. NO donor and MEK inhibitor synergistically inhibit proliferation and invasion of cancer cells.
Furuhashi S; Sugita H; Takamori H; Horino K; Nakahara O; Okabe H; Miyake K; Tanaka H; Beppu T; Baba H
Int J Oncol; 2012 Mar; 40(3):807-15. PubMed ID: 22025280
[TBL] [Abstract][Full Text] [Related]
8. Negative regulation of the LKB1/AMPK pathway by ERK in human acute myeloid leukemia cells.
Kawashima I; Mitsumori T; Nozaki Y; Yamamoto T; Shobu-Sueki Y; Nakajima K; Kirito K
Exp Hematol; 2015 Jul; 43(7):524-33.e1. PubMed ID: 25846811
[TBL] [Abstract][Full Text] [Related]
9. IGF-I stimulates IL-8 production in the promyelocytic cell line HL-60 through activation of extracellular signal-regulated protein kinase.
Kooijman R; Coppens A; Hooghe-Peters E
Cell Signal; 2003 Dec; 15(12):1091-8. PubMed ID: 14575864
[TBL] [Abstract][Full Text] [Related]
10. PTEN sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for the blockade of cell proliferation.
Jang K; Kim M; Seo HS; Shin I
Oncol Rep; 2010 Sep; 24(3):787-93. PubMed ID: 20664988
[TBL] [Abstract][Full Text] [Related]
11. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126.
Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM
J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
13. MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.
Yip-Schneider MT; Schmidt CM
Pancreas; 2003 Nov; 27(4):337-44. PubMed ID: 14576498
[TBL] [Abstract][Full Text] [Related]
14. Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway.
Fukazawa H; Noguchi K; Murakami Y; Uehara Y
Mol Cancer Ther; 2002 Mar; 1(5):303-9. PubMed ID: 12489846
[TBL] [Abstract][Full Text] [Related]
15. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways.
Bancroft CC; Chen Z; Dong G; Sunwoo JB; Yeh N; Park C; Van Waes C
Clin Cancer Res; 2001 Feb; 7(2):435-42. PubMed ID: 11234901
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells.
Xiao RZ; He CM; Xiong MJ; Ruan XX; Wang LL; Chen Y; Lin DJ
Oncol Rep; 2013 May; 29(5):1895-901. PubMed ID: 23467984
[TBL] [Abstract][Full Text] [Related]
17. Neuropeptide Y receptor mediates activation of ERK1/2 via transactivation of the IGF receptor.
Lecat S; Belemnaba L; Galzi JL; Bucher B
Cell Signal; 2015 Jul; 27(7):1297-304. PubMed ID: 25817573
[TBL] [Abstract][Full Text] [Related]
18. Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells.
Gingras S; Côté S; Simard J
Mol Endocrinol; 2000 Feb; 14(2):229-40. PubMed ID: 10674396
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor β and Ras/MEK/ERK signaling regulate the expression level of a novel tumor suppressor Lefty.
Miyata N; Azuma T; Hozawa S; Higuchi H; Yokoyama A; Kabashima A; Igarashi T; Saeki K; Hibi T
Pancreas; 2012 Jul; 41(5):745-52. PubMed ID: 22441145
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
Ripple MO; Kalmadi S; Eastman A
Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]